Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 225

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1B
Chunk 225
---
 2023, the Company
adopted the Renovaro Biosciences Inc. 2023 Equity Incentive Plan (the “2023 Plan”). The 2023 Plan replaced the 2019 Plan.
The 2023 Plan provides that the maximum aggregate number of shares of the Company’s Common Stock reserved and available for issuance
under the 2023 Plan was the sum of (1) 4,000,000 new shares, and (2) the number of shares available for the grant of awards as of the
effective date under the 2019 Plan. Any awards outstanding under the 2019 Plan as of the date of adoption of the 2023 Plan remain subject
to and will be available under the 2019 Plan, and any shares subject to outstanding awards under the 2019 Plan that subsequently expire,
terminate, or are surrendered or forfeited for any reason without issuance of shares automatically become available for issuance under
the 2023 Plan.

 The Company granted options
to purchase 1,000,000 shares of Common Stock to employees with a five-year vesting period during the year end June 30, 2025 under the
2019 and 2023 Plan. For the year ended June 30, 2024, the Company granted options to purchase zero shares of Common Stock to employees
with a five-year vesting period under the 2019 and 2023 Plan.

 The Company granted options
to purchase zero shares of Common Stock to employees with a three-year vesting period during the year end June 30, 2025 under the 2019
and 2023 Plan. For the year ended June 30, 2024, the Company granted options to purchase 369,500 shares to employees with a three-year
vesting period under the 2019 and 2023 Plan.

 The Company granted options
to purchase 1,850,000 shares of Common Stock to employees with a two-year vesting period during the year end June 30, 2025 under the 2019
and 2023 Plan. For the year ended June 30, 2024, the Company granted options to purchase zero shares of Common Stock to employees with
a two-year vesting period under the 2019 and 2023 Plan.

During the years ended June 30,
2025 and 2024, the Company granted options to purchase 362,904 and 424,412 shares, respectively, to the